SOLV · Solventum Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings per share non-GAAP | $4.02 | Six months ended June 30, 2026 | +32.7% |
|
|
|||
| Adjusted operating income margin non-GAAP | 24.2% | Six months ended June 30, 2026 | — |
|
|
|||
| Free cash flow non-GAAP | -$129M | Six months ended June 30, 2026 | — |
|
|
|||
| Operating income margin non-GAAP | 24.2% | Six months ended June 30, 2026 | +16.3% |
|
|
|||
| Organic sales growth non-GAAP | 5.8% | Six months ended June 30, 2026 | — |
|
|
|||
| Reported sales growth | -3.7% | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SOLV
this stock
Solventum Corp
|
$15.08B | +11.8% | +0.9% | 10.8 | 2.1% |
|
ISRG
Intuitive Surgical Inc
|
$139.37B | -30.3% | +20.5% | 45.3 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.96B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$46.99B | -14.9% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.89B | -5.8% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SOLV | +6.8% | +9.0% | +21.9% | +3.7% | +11.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +6.4% | +4.5% | +8.2% | -0.2% | -2.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.